Silvercrest Asset Management Group 13F: Cuts ABT Stake by $2.5M

Silvercrest Asset Management Cuts Position in Abbott Laboratories

Silvercrest Asset Management Group filed a Form 13F with the SEC covering the period, revealing a smaller position in Abbott Laboratories (NYSE: ABT). The firm trimmed its holdings by 27,335 shares, working out to a 2.4% reduction for the quarter. Because 13F filings look backward, this report reflects holdings as of that date and may not represent the firm's current portfolio.

Details of the Reduction

Before the adjustment, Silvercrest held 1,121,935 shares of the healthcare company. After selling 27,335 shares during the period, the firm closed the quarter with 1,094,600 shares. Based on market prices at the time, the remaining stake was valued at roughly $99.5 million.

Abbott Laboratories Stock and Valuation

Shares of Abbott Laboratories traded near $90.90, sitting closer to the lower end of their 52-week range between $81.97 and $132.03. The company carries a price-to-earnings ratio of 33.77 alongside a forward price-to-earnings ratio of 17.26.

Dividend Profile

Income-focused investors note that Abbott Laboratories pays a dividend yielding 2.41%. The payout ratio sits at 78.71%, showing how much of the company's earnings go directly toward shareholder dividends.

Wall Street Analyst Views

Wall Street firms continue to update their views on the company. On October 16, 2026, TD Cowen reiterated its Buy rating with a $135.00 price target. Earlier in October, Barclays initiated coverage with an Overweight rating and a $120.00 price target, while Rothschild & Co upgraded the stock to Buy with a $127.00 target on October 2, 2026. Overall, the stock holds a consensus recommendation of Strong Buy from 26 analysts with a mean price target of $120.72.

Inside Abbott Laboratories

Based in Abbott Park, Illinois, Abbott Laboratories discovers, develops, manufactures, and sells health care products globally across four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Led by CEO Mr. Robert B. Ford, the company employs roughly 122,000 people to support its broad portfolio of medical technologies and treatments.

What to Watch at Abbott Laboratories

Investors tracking Abbott Laboratories will look toward the company's next earnings report on October 21, 2026, for fresh updates on revenue and profit margins. Institutional reports like this one offer a snapshot of past portfolio adjustments, and future filings will show whether firms continue to trim or rebuild their stakes.